Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)
HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
At close: 03:56PM HKT
| Previous Close | 1.990 |
| Open | 2.000 |
| Bid | 2.000 x N/A |
| Ask | 2.100 x N/A |
| Day's Range | 2.000 - 2.090 |
| 52 Week Range | 1.790 - 5.700 |
| Volume | |
| Avg. Volume | 45,924 |
| Market Cap | 524.864M |
| Beta (5Y Monthly) | -0.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023
Bioheart (02185.HK), together with its holding subsidiary Angiocare announces the clinical result for Iberis-HTN at China Interventional Therapeutics 2023. Iberis-HTN is a prospective, multicenter, blinded, randomized controlled trial to evaluate the safety and efficacy of the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System for the treatment of primary hypertension (NCT02901704). The study was led by Academician Runlin GAO and Professor Xiongjing JIANG from Fuwai Hos
© 2024 Yahoo. All rights reserved.